Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Will Pay Ciphergen $2M When USPTO Re-Issues SELDI Patent

NEW YORK (GenomeWeb News) — Bio-Rad Laboratories will pay Ciphergen $2 million once the US Patent and Trademark Office re-issues a SELDI mass-spectrometry-related patent, Ciphergen said yesterday.
Ciphergen said the USPTO has given it a notice of intent to issue a Re-examination Certificate for the patent, entitled “Method and apparatus for desorption and ionization of analytes” and assigned to the Baylor College of Medicine.
Ciphergen said the payment is part of Bio-Rad’s acquisition of Ciphergen’s proteomic tools business last year.